Jun 30, 2020

CVS Health Q2 2020 Earnings Report

CVS Health's Q2 2020 performance was marked by strong enterprise results, driven by diversified assets amidst the COVID-19 pandemic. The company raised its full-year EPS and cash flow guidance.

Key Takeaways

CVS Health reported a 3.0% increase in total revenues, reaching $65.3 billion. GAAP operating income increased by 40.5% to $4.7 billion, and adjusted operating income increased by 32.2% to $5.3 billion. GAAP diluted earnings per share was $2.26, and adjusted EPS was $2.64.

Total revenues increased by 3.0% to $65.3 billion, driven by growth across all segments.

GAAP operating income increased by 40.5% to $4.7 billion, and adjusted operating income increased by 32.2% to $5.3 billion.

GAAP diluted earnings per share reached $2.26, and adjusted EPS was $2.64.

The company raised its full-year 2020 GAAP diluted EPS guidance range to $5.59 to $5.72 and adjusted EPS guidance range to $7.14 to $7.27.

Total Revenue
$65.3B
Previous year: $63.4B
+3.0%
EPS
$2.64
Previous year: $1.89
+39.7%
Medical membership
23.6M
Previous year: 22.8M
+3.5%
Gross Profit
$13.3B
Previous year: $11.4B
+17.4%
Cash and Equivalents
$14.9B
Previous year: $6.06B
+145.2%
Free Cash Flow
$6.67B
Previous year: $4.77B
+40.0%
Total Assets
$235B
Previous year: $219B
+7.6%

CVS Health

CVS Health

CVS Health Revenue by Segment

Forward Guidance

CVS Health raised its full year 2020 GAAP diluted EPS guidance range to $5.59 to $5.72 from $5.47 to $5.60 and its full year 2020 Adjusted EPS guidance range to $7.14 to $7.27 from $7.04 to $7.17 and also raised its full year 2020 cash flow from operations guidance range to $11.0 billion to $11.5 billion from $10.5 billion to $11.0 billion.

Positive Outlook

  • Raised GAAP diluted EPS guidance range to $5.59 to $5.72 from $5.47 to $5.60
  • Raised Adjusted EPS guidance range to $7.14 to $7.27 from $7.04 to $7.17
  • Raised cash flow from operations guidance range to $11.0 billion to $11.5 billion from $10.5 billion to $11.0 billion
  • Projects higher utilization in its Health Care Benefits segment in the second half of 2020 than in the first half of 2020
  • Reflects an update to its estimated full year effective income tax rate

Challenges Ahead

  • Acknowledges the inherent and unprecedented uncertainty surrounding the ongoing COVID-19 pandemic and its impact
  • Projects continued significant COVID-19 related investments, including operating costs, in the remainder of the year.
  • Risks and uncertainties related to the COVID-19 pandemic
  • The pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns
  • The timing, scope and impact of stimulus legislation and other federal, state and local governmental responses to the pandemic